Operation Time

With Obesity on the Rise, New Bariatric Study Finds Surgeons Don't Follow the Same Best Practices, Even Within the Same Hospital

Retrieved on: 
Monday, November 20, 2023
Sleeve gastrectomy, PALO, Research, Entrepreneurship, Weight loss, Dean (education), Liver, Risk, Surgeon, Insurance, Patient, Cleveland Clinic, Most, Threat Intelligence Platform, OP, Pancreas, Rectum, Obesity, American College, Educational technology, Gallbladder, Uterus, Hospital, Innovation, News, Bariatric surgery, Health, Operation Time, Health insurance, Dentistry, Medical device

PALO ALTO, Calif., Nov. 20, 2023 /PRNewswire/ -- Theator, a leading AI driven health-technology company, today announced the findings of its in-depth analysis on bariatric surgery. Coinciding with news of insurance companies continuing to refuse coverage of GLP-1 drugs for weight loss and obesity associated with a yearly excess of $1,861 in health costs per person, Theator set out to gather insights into how longer lasting solutions like bariatric surgeries were stacking up across the board. 

Key Points: 
  • While 82% of procedures reinforced the staple line, 18% did not; which can lead to complications.
  • Theator's data analysis also highlighted that surgeons across systems do not follow the same protocols.
  • While many of these metrics were previously unknown, Theator revealed that on average it took surgeons 13.2 minutes to conduct the gastric transection step.
  • Most recently, Theator's Surgical Intelligence Platform was recognized by Fast Company as part of their annual list of Most Innovative Companies for 2023.

Global Hernia Mesh Devices Market Size, Share & Trends Analysis Report 2023: Market to Reach $8.3 Billion by 2030 - Innovation in Enhancing Patient Outcomes Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 13, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Biotechnology, Incidence, Femoral hernia, Hernia, Capillary action through synthetic mesh, Prevalence, Inguinal hernia, USD, Biomesh, Growth, Incisional hernia, Operation Time, Patient, Thermoplastic, Pharmaceutical industry

The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global hernia mesh devices market size is expected to reach USD 8.3 billion by 2030.
  • Additionally, the market benefits from a favorable reimbursement scenario, which encourages patients to opt for hernia surgeries, further boosting market growth.
  • Among hernia types, inguinal hernia repair devices hold a substantial market share, thanks to the wide range of available mesh products designed specifically for inguinal repair.

Captiva Spine Announces Completion of First U.S. Cases with the New WatchTower™ Spine Navigation System

Retrieved on: 
Tuesday, May 2, 2023
ASC, CT, Radiation, Workflow, 3D, Watchtower, Captiva, Spine, Operation Time, 2D, Patient, Risk, Vision-guided robot systems, Safety, Bookbinding, Medical imaging

JUPITER, Fla., May 2, 2023 /PRNewswire-PRWeb/ -- Captiva Spine, a spinal technology organization dedicated to providing clinical and economical solutions in spine care, announced the completion of the first U.S. case series using their new state-of-the-art WatchTower Spine Navigation System. The surgeries were performed by Dr. Hunaldo Villalobos of the Central Florida Neurosurgery Institute at facilities in the Orlando, FL, area.

Key Points: 
  • Captiva Spine, a spinal technology organization dedicated to providing clinical and economical solutions in spine care, announced the completion of the first U.S. case series using their new state-of-the-art WatchTower™ Spine Navigation System.
  • JUPITER, Fla., May 2, 2023 /PRNewswire-PRWeb/ -- Captiva Spine, a spinal technology organization dedicated to providing clinical and economical solutions in spine care, announced the completion of the first U.S. case series using their new state-of-the-art WatchTower Spine Navigation System.
  • Dale Mitchell, President of Captiva Spine, expressed excitement over the first US cases using WatchTower Spine Navigation System, stating, "We are thrilled to see our technology making a real impact in the operating room.
  • For more information about the Captiva Spine WatchTower Spine Navigation and Robotics System and our other spinal fusion solutions, please visit http://www.captivaspine.com/spine-navigation

Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer During Lumpectomy

Retrieved on: 
Thursday, April 27, 2023
Biotechnology, Health, Women, Oncology, Men, Health Technology, Medical Devices, Hospitals, Surgery, Consumer, Clinical Trials, Surgeon, The New England Journal of Medicine, Marie Cassidy, New Drug Application, NDA, Cancer, Operation Time, Optical flow, Multimedia, Federal, Research, Doctor of Philosophy, Lumpectomy, NEJM, Harvard Medical School, PMA, MD, Patient, Neoplasm, Hospital, DVS, FDA, Massachusetts General Hospital, Breast cancer, Society, Safety, Medical imaging, Lumicel Animation Studios

The results highlight the safety and effectiveness findings of the company’s pivotal trial of its investigational Lumicell™ Direct Visualization System (DVS) to identify residual breast cancer following removal of the primary specimen during initial lumpectomy.

Key Points: 
  • The results highlight the safety and effectiveness findings of the company’s pivotal trial of its investigational Lumicell™ Direct Visualization System (DVS) to identify residual breast cancer following removal of the primary specimen during initial lumpectomy.
  • The Lumicell DVS and LUMISIGHT are limited by Federal (or United States) law to investigational use only.
  • (Photo: Business Wire)
    In the INSITE trial, the Lumicell DVS identified cancer remaining after the standard of care lumpectomy procedure in approximately 8% of patients.
  • The additional residual cancer identified by the Lumicell DVS measured 1-13 mm and included areas of low- and high-grade tumor in patients across all tumor types.

restor3d Receives FDA Clearance of Patient Specific Resection Guides for use with the Kinos Axiom Total Ankle System

Retrieved on: 
Thursday, April 6, 2023
Biotechnology, Surgery, Health, FDA, Artificial Intelligence, Medical Devices, Health Technology, Technology, OR, Operation Time, PSR, Porosity, Multimedia, MD, Axiom, SVP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TIDAL, Food, Medical imaging

restor3d, a research-driven medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System.

Key Points: 
  • restor3d, a research-driven medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System.
  • The Axiom PSR (patient-specific resection) System is additively manufactured from titanium alloy, making it the first all-metal, patient-specific instrument system cleared for use with an ankle arthroplasty system.
  • The all-metal resection guides, 3d printed at restor3d’s facility in Durham, NC, ensure ideal anatomic fit and exact placement of the pre-planned cut required to place the Kinos Axiom Total Ankle System Implants.
  • Integrating TIDAL Technology’s interconnected porosity, the Axiom PSR System is the latest addition to restor3d’s lower extremity portfolio, which features the Kinos Axiom Total Ankle System, TIDAL Osteotomy Wedge Systems and MTP Hemiarthroplasty System, and the mobile companion App for the r3id Personalized Surgery platform.

Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures

Retrieved on: 
Tuesday, March 21, 2023
Bone, Metro, Dipterocarpus conformis, Probability, University, Greater, Education, Anatomy, University of Washington, Orthopaedic Research Society, Operation Time, Marketing, Journal, TKA, Patient, Length of stay, Convention (norm), Knee, Pharmaceutical industry, Dentistry, Medical device

Independent surveys and Conformis market research show that most of the growing total knee replacement patient population is unaware of stark differences in knee replacement systems, and simply receives the brand of knee replacement system used most frequently by their surgeon.

Key Points: 
  • Independent surveys and Conformis market research show that most of the growing total knee replacement patient population is unaware of stark differences in knee replacement systems, and simply receives the brand of knee replacement system used most frequently by their surgeon.
  • Lower total direct costs for hospital admissions, with variables such as operative time and length of stay favoring fully personalized implants3.
  • The Conformis patient awareness campaign, whose primary television spot is seen here , is currently running in the Greater Boston-Seacoast New Hampshire and Metro Minneapolis-St. Paul markets through March.
  • For more information about Conformis and the company’s fully personalized and made-to-measure knee replacement systems, please visit www.conformis.com .

NuVasive Celebrates 20-Year Milestone of the XLIF Procedure

Retrieved on: 
Monday, March 13, 2023
Spine, E pluribus unum, Bleeding, NUVA, Rush University Medical Center, NuVasive, Pain, Houston Methodist Hospital, Economics, MIS, Operation Time, Risk management, Pathology, SAN, Complex, X360, Partnership, Houston, Health care, Hospital, Medical imaging, Bookbinding, Pulse

SAN DIEGO, March 13, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the 20-year milestone achievement of its lateral lumbar procedure, extreme lateral interbody fusion (XLIF).

Key Points: 
  • "20 years ago, we set out to make spine surgery more reproducible and improve patient outcomes through the development and introduction of the XLIF procedure," said Ryan Donahoe, chief technology officer at NuVasive.
  • "It's been quite a journey since I started working with NuVasive in 2001, being attracted to the vision of making spine surgery better.
  • "When paired with the enabling technologies within Pulse, XLIF unlocks even more clinical value for both the surgeon and the patient."
  • Building on the legacy of XLIF, the Company has since launched its X360, P360, C360 and Complex procedural portfolios.

Global Hernia Mesh Devices Market Report to 2030 - Featuring Medtronic, Johnson & Johnson, Atrium and Life Cell Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Health, Medical Supplies, Medical Devices, BD, Government, Ethicon, Johnson & Johnson, Hernia, Echo, Patient, Pain, Incidence, Echo II, Recurrence, Chapter Three, Growth, FDA, Operation Time, U.S. FDA, Risk management, Pharmaceutical industry

The reimbursement scenario for hernia mesh devices is favorable, which encourages patients to opt for open or laparoscopic surgery.

Key Points: 
  • The reimbursement scenario for hernia mesh devices is favorable, which encourages patients to opt for open or laparoscopic surgery.
  • Patients have easy access to detailed reimbursement codes and ratios, which are made available by the government and industry players.
  • The codes are granulated to types of hernias, (primary or recurrent) and the method of surgery (open or laparoscopic).
  • In March 2020, Johnson & Johnson's Ethicon wins a lawsuit against polypropylene hernia mesh.

CairnSurgical Announces First Patients Treated in Europe With Breast Cancer Locator System

Retrieved on: 
Tuesday, January 24, 2023
Radiology, Biotechnology, Surgery, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Medicine, Woman, Dartmouth, Trial of the century, MDR, Breast, Breast cancer, MRI, Dartmouth–Hitchcock Medical Center, Patient, BCL, BCS, Anesthesia, Skin, Geisel School of Medicine, Visualizer, Neoplasm, Pathology, Disease, FDA, Operation Time, Surgeon, 3D, Dentistry, Medical imaging, MD

CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patients have been treated in its European post market clinical study of the Breast Cancer Locator (BCLTM) System .

Key Points: 
  • CairnSurgical, Inc. , an innovator striving to make breast cancer surgery more precise, announced today that the first patients have been treated in its European post market clinical study of the Breast Cancer Locator (BCLTM) System .
  • “We are delighted that in our first case using the BCL technology we were able to achieve a negative margin, with no detectable cancer present after the breast tumor was removed.
  • Hisham Fansa, head of the Breast Center and head of plastic surgery for Spital Zollikerberg, and co-principal investigator of the study.
  • In two studies of the BCL System, published in the Annals of Surgical Oncology2 and in Surgical Oncology3, clear tumor margins were achieved in all 33 patients.

Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update

Retrieved on: 
Monday, January 9, 2023
ISU, European Medical Writers Association, PARK, MDR, PMDA, Image, CE marking, Digital, Leonardo da Vinci, Operation Time, GYN, Anatomy, Surgeon, NYSE, 3D, Kitakyushu, U.S. FDA, Growth, Acceleration, Patient, Urology, Sale, General surgery, Freedom, RESEARCH, Gynaecology, TRUST, CIS, Investment, Dentistry, Medical device, Security (finance), Video game, Medicine

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update.
  • During the fourth quarter of 2022, the Company initiated five new Senhance Surgical System placements, two in Germany, two in Japan, and one in the CIS region.
  • In 2022, the Company initiated nine new Senhance Surgical System placements: four in Germany, three in Japan, and two in the CIS region.
  • For the quarter ended December 31, 2022, the Company estimates preliminary unaudited revenue of approximately $2.2 - $2.8 million.